News

TH-302 is a proprietary tumor selective Hypoxia-Activated Prodrug (HAP) that specifically targets tumor hypoxia. Threshold Pharma is expected to enroll approximately 165 patients with previously untreated, locally advanced,

Evotec said that the advancement of EVT 101 into Phase II study is a part of an alliance between Evotec and Roche. Under this alliance Evotec is responsible

The FDA has indicated that the single 50-patient open-label Phase 3 study of Corlux, which is being conducted at 20 medical facilities throughout the US, may provide a

Pharma Omnium has increased its research efforts by acquiring two French biotech firms, Mutabilis and Cellvir in June 2009 and May 2010 respectively. The Mutabilis researchers, who were

Zegerid, a registered trademark of Santarus, is known to contain omeprazole, a proton pump inhibitor (PPI), and sodium bicarbonate, an antacid, which raises the gastric pH and thus

Model N is expected to invest 80 to 100 crores in its Indian operations over the next three years by recruiting in the areas of product development, professional

HuCAL-derived is a fully human antibody in the therapeutic area of musculoskeletal diseases. MorphoSys said that in 2010 between four and six partnered programs could enter clinical trials.

Rifapentine comes under rifamycin class, which according to Sanofi-aventis has a higher inhibitory activity against Mycobacterium tuberculosis and a longer half-life than rifampin. With the objective of shortening

Dr Scangos has an experience of nearly 25 years in the biotechnology and pharmaceutical industries. Prior to joining Biogen Idec, he served as president and CEO at Exelixis